List of Excipients in Branded Drug LACOSAMIDE ORAL SOLUTION

« Back to Dashboard

Generic Drugs Containing LACOSAMIDE ORAL SOLUTION

Company	Ingredient	NDC	Excipient
Apotex Corp	lacosamide	60505-0405	ACESULFAME POTASSIUM
Apotex Corp	lacosamide	60505-0405	ALCOHOL
Apotex Corp	lacosamide	60505-0405	ANHYDROUS CITRIC ACID
Apotex Corp	lacosamide	60505-0405	CARBOXYMETHYLCELLULOSE SODIUM
Apotex Corp	lacosamide	60505-0405	GLYCERIN
Apotex Corp	lacosamide	60505-0405	METHYLPARABEN
Apotex Corp	lacosamide	60505-0405	POLYETHYLENE GLYCOL 4000

What are the Most Frequently-Used Excipients in LACOSAMIDE ORAL SOLUTION?

# Of NDCs	Excipient
9	ACESULFAME POTASSIUM
1	ACETIC ACID
1	ALCOHOL
1	AMMONIUM GLYCYRRHIZATE
9	ANHYDROUS CITRIC ACID
1	ASPARTAME
1	ASPARTAME ACESULFAME

Lacosamide Oral Solution Excipient Strategy and Commercial Opportunities

Last updated: August 26, 2026

Lacosamide oral solution is a mature generic small-molecule opportunity with limited compound-patent protection but continuing value in pediatric epilepsy, dysphagia, enteral feeding, hospital step-down therapy, and markets where tablets are less practical. The reference product, Vimpat oral solution, uses a 10 mg/mL aqueous formulation with glycerol, polyethylene glycol 400, sweetener, citrate buffering, parabens, flavor and purified water. The strongest commercial strategies are differentiated taste masking, preservative alternatives, device-led dosing, unit-dose packaging and low-cost global manufacture.

Commercial assessment: generic entry is legally accessible, but price competition is likely in standard multidose bottles. A differentiated formulation can preserve margin if it solves administration, palatability, preservative, stability or supply-chain problems.

What is lacosamide oral solution used for?

Lacosamide is an antiseizure medication approved for the treatment of partial-onset seizures. In the United States, the reference product is Vimpat, marketed by UCB. The oral solution contains 10 mg of lacosamide per mL and is administered twice daily. FDA labeling covers use in adults and pediatric patients aged 1 month and older, depending on the specific indication and labeling version.[1]

The oral solution is commercially relevant for patients who:

• Cannot swallow tablets or capsules.
• Require weight-based pediatric dosing.
• Receive medication through an enteral feeding tube.
• Transition from intravenous lacosamide to oral therapy.
• Need dose titration below available tablet strengths.
• Have neurologic, cognitive or motor impairment.

Lacosamide has high oral bioavailability and is available in tablets, oral solution and intravenous injection. The oral solution does not require an absorption-enhancing excipient system. Its principal formulation challenges are palatability, chemical and microbiological stability, excipient tolerability and accurate dosing.

What excipients are used in Vimpat oral solution?

The reference oral solution is a preserved, buffered aqueous formulation. The FDA prescribing information identifies the following inactive ingredients:[1]

Excipient	Primary formulation function
Glycerol	Co-solvent, humectant, mouthfeel modifier and sweetness contributor
Polyethylene glycol 400	Co-solvent and solubilization aid
Sodium saccharin	High-intensity sweetener
Sodium citrate	Buffering agent and pH control
Citric acid	Acidifying agent and buffer component
Methylparaben	Antimicrobial preservative
Propylparaben	Antimicrobial preservative
Flavor	Taste and odor masking
Purified water	Vehicle

The formulation is designed around lacosamide’s favorable aqueous solubility. The excipient system does not need lipid vehicles, cyclodextrin complexes or surfactant-heavy solubilization. That reduces formulation complexity and supports a broad generic development pathway.

The reference formulation also establishes a regulatory benchmark. A generic manufacturer does not need to copy every excipient, but any change must remain compatible with pharmaceutical quality, safety, stability, dose uniformity and container-closure requirements.

How should a generic manufacturer design the excipient system?

A standard generic strategy should begin with a Q1/Q2-oriented formulation that closely resembles the reference product. This reduces development risk and simplifies justification of excipient selection. A differentiated strategy can then target specific weaknesses of the reference product.

Core design objectives

The formulation should meet five requirements:

1. Maintain 10 mg/mL lacosamide concentration.
2. Deliver consistent dose volume across the shelf life.
3. Control pH and prevent precipitation or crystallization.
4. Limit microbial growth after opening.
5. Improve taste without increasing excipient burden.

The target pH should be selected through forced-degradation studies rather than copied solely from the label. Lacosamide degradation, preservative efficacy, flavor stability and container compatibility should be assessed across the proposed pH range.

Sweetener and taste-masking strategy

Lacosamide can produce an unpleasant taste that becomes more noticeable in pediatric and dysphagia populations. Sodium saccharin provides intense sweetness at low concentration but can leave a lingering aftertaste. Glycerol contributes body and sweetness but can increase viscosity and gastrointestinal tolerability concerns at higher levels.

Potential alternatives include:

• Sucralose for a cleaner sweetness profile.
• Acesulfame potassium in combination with another sweetener.
• Polyols such as sorbitol or xylitol, subject to gastrointestinal tolerance.
• Flavor systems selected through pediatric taste panels.
• Ion-exchange resins or polymeric taste-masking systems for more advanced products.
• Viscosity modifiers that reduce immediate contact with taste receptors.

Taste masking is commercially valuable, but aggressive masking can increase excipient load, osmolality and manufacturing complexity. A conventional sweetener-flavor system is more appropriate for a low-cost generic. A premium pediatric product may justify a more complex approach if it produces measurable adherence or administration benefits.

Preservative strategy

The reference product uses methylparaben and propylparaben. This creates several opportunities:

• A preserved formulation with a different preservative system.
• A lower-paraben or paraben-free product.
• A preservative-free unit-dose product.
• A concentrated formulation for pharmacy compounding or institutional use.
• Packaging that reduces repeated microbial exposure.

Potential preservative alternatives include potassium sorbate, sodium benzoate or phenoxyethanol, subject to pH dependence, safety limits, taste impact and compatibility. Each alternative requires preservative effectiveness testing under USP <51> or the applicable local standard.

A preservative-free formulation is attractive for pediatric and chronic-use positioning, but it shifts the burden to packaging. Unit-dose cups, blow-fill-seal containers or single-use oral syringes can reduce contamination risk. The resulting product may have higher packaging costs but a stronger institutional and specialty-pharmacy proposition.

What formulation patents protect lacosamide oral solution?

The principal commercial patent risk historically centered on lacosamide itself and the branded product’s listed patents, rather than a durable, stand-alone oral-solution platform. Lacosamide was disclosed in U.S. Patent No. 6,048,899, assigned to Schwarz Pharma, a predecessor of UCB. The patent covered lacosamide compounds and related pharmaceutical use.[2]

The original U.S. compound-patent term expired in the early 2020s, with pediatric exclusivity extending the effective protection period. FDA approval of generic lacosamide products followed the end of the principal regulatory exclusivity period. The reference product’s current Orange Book status must be evaluated by dosage form and listed patent at the time of an ANDA filing.[3]

Protection category	Commercial significance
Lacosamide compound patent	Historically the main barrier; no longer the principal U.S. barrier
Pediatric exclusivity	Extended the effective exclusivity period after the base patent term
Method-of-use patents	May affect specific seizure indications or patient populations
Oral-solution formulation patents	Potentially relevant if separately listed and enforceable
Manufacturing patents	Can affect API or finished-dose sourcing without necessarily blocking generic launch
Regulatory exclusivity	No current new-drug exclusivity advantage comparable to a recently approved product

A formulation patent would need to claim a technically meaningful feature, such as a specific preservative system, pH range, stability profile, taste-masking architecture, packaging configuration or manufacturing process. Generic manufacturers can often design around such claims by changing the excipient system or container.

What is the FDA regulatory status of lacosamide oral solution?

Lacosamide oral solution is an FDA-approved dosage form under the Vimpat NDA. Generic versions are eligible for approval through the abbreviated new drug application pathway because lacosamide is an established small-molecule drug with an FDA reference listed drug.[1,4]

For an oral solution, the regulatory emphasis differs from tablet bioequivalence:

• The active concentration must be equivalent.
• The formulation must meet pharmaceutical quality standards.
• Dose delivery must be accurate.
• Inactive ingredients must be justified for the route, age group and concentration.
• Stability and preservative effectiveness must be demonstrated.
• Container-closure compatibility must be established.
• The product must be suitable for oral administration and, where claimed, enteral-tube use.

Because lacosamide oral solution is a solution rather than a suspension, conventional in vivo bioequivalence requirements may be less burdensome than for solid oral products. FDA’s product-specific guidance and ANDA review requirements control the actual evidence package.[4]

A manufacturer seeking a differentiated formulation may need additional bridging work if it changes excipients materially. The product must also address labeling differences involving allergens, sugar content, alcohol content, preservatives, sodium, osmolality and administration devices.

What generic entry risks exist for lacosamide oral solution?

The legal entry risk is lower than the commercial risk. The compound-patent barrier has largely expired, while the market can support several suppliers. The main risks are:

Risk	Impact on launch
Orange Book patent certification	May delay approval or trigger Paragraph IV litigation
Listed method-of-use patent	Can require a carve-out or labeling strategy
Pediatric labeling requirements	May limit substitution or create additional development work
Preservative failure	Can cause regulatory deficiency or recall exposure
Taste rejection	Can reduce pharmacy and caregiver adoption
Bottle and syringe compatibility	Can create dose-delivery and stability problems
Low market price	Can make standard multidose products unattractive
API supply concentration	Can disrupt cost and continuity of supply
Global excipient restrictions	Can require separate regional formulations

A Paragraph IV challenge is relevant if an ANDA applicant asserts that an Orange Book-listed patent is invalid, unenforceable or not infringed. For lacosamide oral solution, the practical value of Paragraph IV activity depends on whether a listed patent specifically covers the proposed dosage form or a method that the generic labeling would induce.

A Paragraph IV notice can create litigation risk under the Hatch-Waxman framework, but the absence of a formulation-specific patent reduces the likelihood that an oral-solution launch will face a long-duration product-specific injunction.

Which companies are challenging the lacosamide market?

The lacosamide market includes UCB as the reference-product sponsor and multiple generic manufacturers. Generic competition has involved established U.S., European and Indian manufacturers, with product availability varying by jurisdiction and dosage form.

The competitive field typically includes:

• Large generic companies with national pharmacy distribution.
• Specialty manufacturers focused on neurology.
• Contract manufacturers supplying regional marketers.
• Hospital suppliers offering oral and injectable presentations.
• International companies using local registration pathways.

The commercial advantage is unlikely to come from the active ingredient. It will come from supply reliability, customer-specific packaging, pediatric usability, pricing, regulatory reach and differentiated excipient positioning.

How does lacosamide oral solution compare with competing antiseizure liquids?

Lacosamide competes with other liquid antiseizure products, including levetiracetam oral solution, valproic acid solution, carbamazepine suspension and oxcarbazepine suspension. The comparison is not based only on seizure control. Administration, dosing frequency, taste, excipient burden and drug-interaction profile affect prescribing and caregiver choice.

Product	Dosage form	Formulation issue	Commercial implication
Lacosamide	Clear oral solution	Taste, preservative and dosing-device optimization	Good platform for pediatric and dysphagia positioning
Levetiracetam	Oral solution	High generic competition and taste management	Price-sensitive market
Valproic acid	Solution or syrup	Strong taste and tolerability concerns	Greater need for palatability work
Carbamazepine	Suspension	Physical stability and dose uniformity	More complex than a true solution
Oxcarbazepine	Suspension	Sedimentation and redispersibility	Device and shaking instructions matter

Lacosamide’s clear solution format is an advantage over suspensions because it avoids sedimentation and redispersion failures. It also supports smaller dose increments. The main weakness is that a clear, sweetened solution provides direct oral exposure to taste-active components.

What commercial opportunities exist for lacosamide oral solution?

Pediatric specialty product

A pediatric-focused product can compete on flavor, syringe accuracy, preservative profile, low osmolality and caregiver instructions. A 10 mg/mL concentration supports weight-based dosing, but a manufacturer could evaluate a lower concentration for very small pediatric doses if it improves measurement accuracy.

Potential commercial claims must remain within approved labeling. Marketing can emphasize administration convenience and formulation attributes, not unsupported adherence or efficacy benefits.

Preservative-free unit-dose packaging

Single-use oral syringes or unit-dose cups can target hospitals, long-term-care facilities and specialty pharmacies. The product can reduce repeated bottle opening and simplify medication administration records.

This format has higher packaging costs and may require a separate stability program. It can still command a premium where contamination control and nursing workflow matter.

Enteral-tube optimized product

An enteral-use formulation should be assessed for:

• Tube flow and clogging.
• Adsorption to polyurethane and silicone tubing.
• Compatibility with feeding formulas.
• Flush-volume requirements.
• Dose recovery after administration.
• Changes in pH or precipitation during tube delivery.

Published or label-supported tube-administration instructions can create a practical commercial advantage, particularly in hospitals and home enteral-care settings.

Global low-cost formulation

A simple aqueous formulation using widely available excipients can support emerging-market registration and contract manufacturing. The best cost structure will generally use:

• Commodity-grade glycerol and PEG 400.
• Standard bottle and oral-syringe components.
• A conventional preservative system.
• Regional flavor variants.
• High-throughput filling lines.

Global manufacturers must assess local restrictions on parabens, sweeteners, flavors and packaging materials. A single global formulation may not be optimal.

Hospital and IV-to-oral conversion

Lacosamide injection is used in situations where oral administration is temporarily unavailable. An oral solution can support conversion once swallowing or enteral access is restored. Hospitals may value a coordinated product portfolio containing injection, tablets and oral solution, even when the oral liquid itself has modest retail volume.

How strong is the patent estate for lacosamide oral solution?

The patent estate is stronger for the historical active-ingredient protection than for a newly developed generic oral-solution formulation. For a new entrant, the principal strengths and weaknesses are:

Estate element	Assessment
Active ingredient	Mature and largely off-patent in the United States
Basic oral solution	Limited differentiation and likely design-around exposure
Novel excipient system	Potentially protectable if supported by unexpected stability, taste or tolerability data
Device-integrated product	Moderate protection potential through packaging and administration claims
Manufacturing process	Useful for supply protection, but often avoidable through alternate process conditions
Pediatric positioning	Commercially valuable but difficult to protect broadly through patents alone

A defensible formulation patent should claim measurable technical performance. Examples include improved chemical stability at a defined pH, reduced preservative concentration with equivalent antimicrobial protection, reduced bitterness using a defined taste-masking system, or improved dose recovery through a specified oral syringe and container combination.

What licensing and partnership opportunities exist?

Lacosamide itself is a generic active ingredient, so licensing value is more likely to arise from technology and distribution than from rights to the molecule.

Potential deal structures include:

• Regional marketing rights for a ready-to-file oral solution.
• Contract development and manufacturing for a specialty generic.
• Co-development of preservative-free unit-dose packaging.
• Flavor technology licensing for pediatric medicines.
• Hospital supply agreements covering injection, tablets and oral solution.
• API supply agreements with dual-sourcing obligations.
• In-licensing of an enteral-tube compatibility platform.

A formulation owner should avoid relying on a broad “lacosamide oral solution” patent position. Commercial protection is stronger when the formulation is paired with proprietary packaging, validated dosing devices, pediatric usability data and reliable supply.

What revenue exposure does lacosamide oral solution create?

The oral solution is generally a smaller revenue component than tablets because most adult patients use solid oral dosage forms. Its value is concentrated in specific populations and channels:

• Pediatric neurology.
• Institutional care.
• Home enteral therapy.
• Hospital discharge conversion.
• Patients with swallowing impairment.
• Markets with limited access to tablets or capsules.

The financial model should separate volume from price. A standard generic bottle may face rapid price erosion once several ANDA holders enter. A differentiated product can maintain better economics, but packaging, stability testing, device assembly and specialty distribution will increase cost of goods.

The most attractive opportunity is usually a focused product with a clear use case rather than an undifferentiated bottle competing solely on price.

Key Takeaways

• Lacosamide oral solution is a 10 mg/mL aqueous dosage form used in epilepsy, particularly where tablets are impractical.
• The reference excipient system uses glycerol, PEG 400, sodium saccharin, citrate buffer, methylparaben, propylparaben, flavor and purified water.
• The main formulation opportunities are taste masking, preservative reduction, unit-dose packaging, enteral-tube compatibility and dosing-device accuracy.
• U.S. compound-patent protection has ended, making formulation execution and commercial positioning more important than molecule access.
• A standard generic product is likely to face price erosion.
• Preservative-free pediatric and institutional products offer the clearest premium opportunity.
• Biosimilar competition is irrelevant because lacosamide is a small-molecule drug. The competitive pathway is generic ANDA approval.
• Manufacturing and supply reliability can be as important as patent protection in a mature lacosamide market.

FAQs

Can lacosamide oral solution be formulated without parabens?

Yes. Alternative preservatives or preservative-free unit-dose packaging can be evaluated, but the formulation must meet antimicrobial effectiveness, stability, safety and container-closure requirements.

Is lacosamide oral solution suitable for feeding tubes?

It can be suitable, but tube compatibility should be demonstrated for the intended tube materials, sizes, flushing procedure and feeding formulas. Labeling should not make enteral-use claims without supporting data.

Does lacosamide oral solution require a complex solubilizer?

Usually no. Lacosamide’s aqueous formulation can use a relatively conventional vehicle and co-solvent system. Excessive use of solubilizers may worsen taste, osmolality and tolerability.

Can a manufacturer patent a new lacosamide liquid formulation?

Yes, if the formulation has a novel and non-obvious technical feature supported by reproducible data. Broad claims covering only lacosamide in liquid form are less likely to provide durable protection after compound-patent expiry.

What packaging is most suitable for pediatric lacosamide solution?

A bottle with a calibrated oral syringe is the standard commercial format. Unit-dose syringes or cups may be preferable for hospitals, long-term-care settings and preservative-free products.

References

1. U.S. Food and Drug Administration. (2023). Vimpat (lacosamide) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. U.S. Patent No. 6,048,899. (2000). Amino acid derivatives. United States Patent and Trademark Office. https://patents.google.com/patent/US6048899

3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2024). Product-specific guidances for generic drug development. https://www.fda.gov/drugs/guidances-drugs/product-specific-guidances-generic-drug-development